Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.
Morrissey
I
I
Chemotherapy Research Unit, University of East London, England.
Smith
J T
JT
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D013141:Spiro Compounds; C084755:DV 7751a; D004917:Erythromycin; C076246:sitafloxacin; D015242:Ofloxacin; D013752:Tetracycline